Analyze Catalogue Methodology Blog Pro Access

⚡ Interrogation des APIs scientifiques en cours…

The quality score for scientific publications. 100% free, 100% independent.

Navigation

Home
Analyze an article
Methodology
Blog
My account

Transparency

Our independence
Methodological transparency
Pro Access
Contact us
Legal notice
Privacy
ToU
ToS
Glossary

Developers

Public API
GitHub

© 2026 Publi-Score.

Free score, forever.

E (14/100) — Non fiable | Bryant A et al. | Publi-Score

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.

Bryant A et al.·American journal of therapeutics·Aug 2021·PMID 34469921

Authors' conclusion

Positive

Does not affect the score

Publi-Score

E

14/100

Not reliableLast updated: 4/18/2026

Fidelity

Full PDFFull analysis — 26/26 evaluable subcriteria

Abstract (PubMed)

Letter responding to criticism of Bryant et al. meta-analysis on ivermectin for COVID-19. Authors defend inclusion of Elgazzar study (removed following complaint, not retracted), and report sensitivity analysis excluding Elgazzar: mortality reduction 49% (aRR 0.51, 95% CI 0.27–0.95), COVID-19 infection reduction 87% (aRR 0.13, 95% CI 0.08–0.21). Authors argue results are 'virtually unchanged' from original analysis.

Category breakdown

Total raw score15.7/100

Integrity coefficient

A. Authors' integrity

COI declaration

0.85

Funding independence

1.00

Coeff. authors = avg(0.85, 1.00) = 0.93

B. Editorial process

Peer review

0.90

Submission→accept. delay

0.90

Coeff. editorial = avg(0.90, 0.90) = 0.90

min(0.93, 0.90) = 0.90← lowest dominates

Final coefficient : 0.90

Final score = 15.7/100 × 0.90 × 100 = 14/100

Save

📄 Export PDF

|

Share

Twitter/X LinkedIn

Contribute

Actions

Analyze another article View the methodology

Information

PMID: 34469921

DOI

10.1097/MJT.0000000000001442

Mode

🤖 Full AI

Grid

v1.1

Scored on

4/18/2026

Quartile

Q3

Similar publications

Contrasted results

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Horby P — 2020 · The New England journal of medicine

Contrasted results

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.

Andrews N — 2022 · The New England journal of medicine

Contrasted results

Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A …

Amanzio M — 2022 · Lancet Reg Health Eur

Contrasted results

The association between COVID-19 vaccination and Bell's palsy

Cirillo N — 2021 · The Lancet. Infectious diseases

Contrasted results

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.

Lopez Bernal J — 2021 · The New England journal of medicine